대한대장항문학회

Purpose:<FONT FACE="Humanst521 BT"> Many reports about efficacy of cetuximab in the prolongation of survival have been published. Especially, the combination of cetuximab and FOLFIRI has a high activity even in prior irinotecan refractory metastatic colorectal cancer (mCRC). Beside small num<FONT FACE="Humanst521 BT">ber of patients, we are trying to evaluate the efficacy and safety of cetuximab combined with FOLFIRI for patients who prior irinotecan chemotherapy had failed. Methods: A r<FONT FACE="Humanst521 BT">etrospective analysis of 26 patients treated with cetuximab with FOLFIRI from July 2006 to August 2007 was done. All patients had already been treated with FOLFIRI chemotherapy in 1<SUP><FONT FACE="Humanst521 BT">st</SUP><FONT FACE="Humanst521 BT"> line or 2<SUP><FONT FACE="Humanst521 BT">nd</SUP><FONT FACE="Humanst521 BT"> line regimens for mCRC. The initial dose of cetuximab was 400 mg/m<SUP><FONT FACE="Humanst521 BT">2</SUP><FONT FACE="Humanst521 BT"> at the 1<SUP><FONT FACE="Humanst521 BT">st</SUP><FONT FACE="Humanst521 BT"> week, after which the dose was 250 mg/m<SUP><FONT FACE="Humanst521 BT">2</SUP><FONT FACE="Humanst521 BT"> weekly plus FOLFIRI biweekly. We defined 1 cycle as 8 weeks, and the responses were evaluated at week 8. Results: The m<FONT FACE="Humanst521 BT">edian follow-up period was 6.2 (1.1∼13.9) months. After 8 weeks, 50% of the patients had a partial response, and the disease control rate was 57.5%. The median time to progression was 3 months. EGFR expression and tumor response had no correlation (P=0.07). Skin reaction and tumor response (median time to progression) had a significant correlation (P= 0.022). Cetuximab did not increase the toxicity asso<FONT FACE="Humanst521 BT">ciated with FOLFIRI, except for an acneiform rash. Conclusions:<FONT FACE="Humanst521 BT"> Cetuximab combined with FOLFIRI chemo<FONT FACE="Humanst521 BT">therapy was effective in treating mCRC patients after FOLFIRI regimen chemotherapy. J Korean Soc Coloproctol 2008;24:345-350